DOP2022000158A - Agonistas heterocíclicos de glp-1 - Google Patents

Agonistas heterocíclicos de glp-1

Info

Publication number
DOP2022000158A
DOP2022000158A DO2022000158A DO2022000158A DOP2022000158A DO P2022000158 A DOP2022000158 A DO P2022000158A DO 2022000158 A DO2022000158 A DO 2022000158A DO 2022000158 A DO2022000158 A DO 2022000158A DO P2022000158 A DOP2022000158 A DO P2022000158A
Authority
DO
Dominican Republic
Prior art keywords
glp
agonists
heterocyclic
formula
solvates
Prior art date
Application number
DO2022000158A
Other languages
English (en)
Inventor
Zhang Haizhen
Meng Qinghua
Lin Xichen
Xing Weigiang
Lei Hui
Jennings Andrew
Original Assignee
Gasherbrum Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gasherbrum Bio Inc filed Critical Gasherbrum Bio Inc
Publication of DOP2022000158A publication Critical patent/DOP2022000158A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta divulgación se refiere a agonistas de GLP-1 de la Fórmula (I): Fórmula (I), que incluyen sales y solvatos aceptables desde el punto de vista farmacéutico de estos, y composiciones farmacéuticas que los incluyen.
DO2022000158A 2020-02-07 2022-08-04 Agonistas heterocíclicos de glp-1 DOP2022000158A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020074537 2020-02-07
CN2020109304 2020-08-14
PCT/CN2021/075488 WO2021155841A1 (en) 2020-02-07 2021-02-05 Heterocyclic glp-1 agonists

Publications (1)

Publication Number Publication Date
DOP2022000158A true DOP2022000158A (es) 2022-09-30

Family

ID=77199190

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2022000158A DOP2022000158A (es) 2020-02-07 2022-08-04 Agonistas heterocíclicos de glp-1

Country Status (20)

Country Link
US (2) US11492365B2 (es)
EP (1) EP4097099B1 (es)
JP (1) JP2023513272A (es)
KR (1) KR20220156535A (es)
CN (1) CN115698003B (es)
AU (1) AU2021216324A1 (es)
CA (1) CA3169975A1 (es)
CL (1) CL2022002105A1 (es)
CO (1) CO2022011065A2 (es)
CR (1) CR20220371A (es)
DK (1) DK4097099T3 (es)
DO (1) DOP2022000158A (es)
FI (1) FI4097099T3 (es)
IL (1) IL295281A (es)
MX (1) MX2022009524A (es)
PE (1) PE20231066A1 (es)
PT (1) PT4097099T (es)
RS (1) RS65877B1 (es)
TW (1) TW202142538A (es)
WO (1) WO2021155841A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
BR112022007627A2 (pt) 2019-10-25 2022-07-12 Gilead Sciences Inc Compostos moduladores do glp-1r
KR20220156535A (ko) 2020-02-07 2022-11-25 가셔브룸 바이오, 인크. 헤테로사이클릭 glp-1 작용제
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2022202864A1 (ja) 2021-03-24 2022-09-29 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
US11858918B2 (en) 2021-04-21 2024-01-02 Gilead Sciences, Inc. GLP-1R modulating compounds
WO2023016546A1 (en) * 2021-08-12 2023-02-16 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2023038039A1 (ja) 2021-09-08 2023-03-16 塩野義製薬株式会社 抗肥満作用の関与する疾患の予防及び治療用医薬
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
CN116003403B (zh) * 2022-11-20 2024-07-23 药康众拓(北京)医药科技有限公司 一种氘代吲唑类化合物、药物组合物及其应用
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
WO2024153070A1 (en) * 2023-01-17 2024-07-25 Fochon Biosciences, Ltd. Glp-1r agonists and uses thereof
CN117447493A (zh) * 2023-12-25 2024-01-26 药康众拓(北京)医药科技有限公司 氘代吲哚嗪类化合物、药物组合物及其应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU212435B (en) 1990-06-07 1996-06-28 Sandoz Ag Herbicidal compositions containing substituted phthalides and heterocyclic phthalides as active ingredient and process for preparation of their active ingredients.
DK0707567T3 (da) 1993-07-09 2001-11-26 Schering Corp Fremgangsmåde til syntese af azetidinoner
JPH08295646A (ja) 1995-04-26 1996-11-12 Teijin Ltd ビス（ヒドロキシエトキシフェニル）化合物の製造方法
US6187774B1 (en) 1996-03-04 2001-02-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and pharmaceutical applications thereof
AU5907898A (en) 1997-01-13 1998-08-03 Penn State Research Foundation, The Asymmetric synthesis and catalysis with chiral heterocyclic compounds
IT1292461B1 (it) 1997-07-03 1999-02-08 Great Lakes Chemical Italia Composti fotocromatici,procedimento per la loro preparazione e loro utilizzo in materiali polimerici
CA2375628A1 (en) 1999-07-09 2001-01-18 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
AU2002222853A1 (en) 2000-12-07 2002-06-18 Astrazeneca Ab Therapeutic compounds
YU46603A (sh) 2000-12-08 2006-05-25 Ortho-Mcneil Pharmaceutical Inc. Indazolil-supstituisana jedinjenja pirolina, kao inhibitori kinaze
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
US7192939B2 (en) 2002-01-30 2007-03-20 Montana State University Pestalotiopsis microsporia isolates and compounds derived therefrom
CN1681789A (zh) 2002-09-17 2005-10-12 埃科特莱茵药品有限公司 1－吡啶－4－基－脲衍生物
US20040259179A1 (en) 2003-05-30 2004-12-23 Gerd Assmann Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
ATE420881T1 (de) 2003-09-17 2009-01-15 Janssen Pharmaceutica Nv Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
EP1706386A1 (en) 2003-12-22 2006-10-04 Eli Lilly And Company Bicyclic derivatives as ppar modulators
EP1751124A4 (en) 2004-05-07 2010-04-14 Exelixis Inc RAF MODULATORS AND METHODS OF USE
WO2005121138A2 (en) 2004-06-03 2005-12-22 Rigel Pharmaceuticals, Inc. Heterotricyclic compounds for use as hcv inhibitors
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
KR20070089908A (ko) 2004-09-21 2007-09-04 아더시스 인코포레이티드 Ｃｒｔｈ２ 수용체 길항작용을 나타내는 인돌 아세트산 및이의 용도
EP2298295B1 (en) 2005-01-31 2013-08-28 Cephalon, Inc. Tumor necrosis factor inhibitors
KR101083506B1 (ko) 2005-07-15 2011-11-16 에프. 호프만-라 로슈 아게 신규한 헤테로아릴 융합된 환형 아민
JP4955009B2 (ja) 2005-11-11 2012-06-20 エフ．ホフマン−ラ ロシュ アーゲー 凝固因子Ｘａの阻害剤としての炭素環式縮合環アミン
MX2008010193A (es) 2006-02-10 2008-11-27 Summit Corp Plc Tratamiento de distrofia muscular de duchenne.
EP2046333A4 (en) 2006-07-24 2010-09-15 Glaxosmithkline Llc THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE
AU2007315848A1 (en) 2006-11-03 2008-05-08 Glenmark Pharmaceuticals S.A. Bridged bicyclic indazoles as cannabinoid receptor ligands
KR20090096636A (ko) 2006-12-22 2009-09-11 노파르티스 아게 Ｄｄｐ-ｉｖ 억제제로서의 1-아미노메틸-ｌ-페닐-시클로헥산 유도체
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
WO2009036275A1 (en) 2007-09-13 2009-03-19 Link Medicine Corporation Treatment of neurodegenerative diseases using indatraline analogs
CN101998959B (zh) 2008-02-06 2013-08-28 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂
TW201000107A (en) 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
US8735391B2 (en) 2008-09-26 2014-05-27 University Of Kansas Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods
TW201040186A (en) 2009-02-05 2010-11-16 Schering Corp Phthalazine-containing antidiabetic compounds
US8455516B2 (en) 2010-01-15 2013-06-04 Touro University HIV-1 fusion inhibitors and methods
WO2012065065A1 (en) 2010-11-12 2012-05-18 Follica, Inc. Methods and compositions for modulating hair growth, wound healing and scar revision
JP5805982B2 (ja) 2011-04-20 2015-11-10 ユニチカ株式会社 ポリアリレート樹脂フィルムおよび気体分離膜
JP5687120B2 (ja) 2011-04-20 2015-03-18 ユニチカ株式会社 ポリアリレート樹脂
KR101401705B1 (ko) 2012-01-31 2014-06-27 울산대학교 산학협력단 로듐 촉매를 이용한 이소인돌린 유도체의 합성방법
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
WO2014055634A1 (en) 2012-10-02 2014-04-10 Yale University Identification of small molecule inhibitors of jumonji at-rich interactive domain 1a (jarid1a) and 1b (jarid1b) histone demethylase
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2014122067A1 (en) * 2013-02-06 2014-08-14 Boehringer Ingelheim International Gmbh New indanyloxydihydrobenzofuranylacetic acids
CN103421006B (zh) 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用
EP2857550A1 (en) 2013-10-02 2015-04-08 Basf Se Amine precursors for depositing graphene
EP2993174A1 (en) * 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridine derivatives and their use in therapy
CN105646459A (zh) 2014-11-13 2016-06-08 上海和辉光电有限公司 一种化合物及其制备方法和应用
WO2016118639A1 (en) 2015-01-20 2016-07-28 The Trustees Of Columbia University In The City Of New York Small molecule oxidizers of pdi and their use
WO2017182983A1 (en) 2016-04-22 2017-10-26 Sabic Global Technologies B.V. Methods of manufacture of 2-aryl-3,3-bis(hydroxyaryl)phthalimidines
EP3445748B1 (en) 2016-04-22 2022-06-15 SHPP Global Technologies B.V. Methods of manufacture of 2-aryl-3,3-bis(4-hydroxyaryl) phthalimidines and polymers derived therefrom
WO2017182986A1 (en) 2016-04-22 2017-10-26 Sabic Global Technologies B.V. Methods of manufacture of 2-aryl-3,3-bis(hydroxyaryl)phthalimidines
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
PL3555064T3 (pl) * 2016-12-16 2023-03-06 Pfizer Inc. Agoności receptora GLP-1 i ich zastosowania
WO2018178947A2 (en) 2017-03-31 2018-10-04 Aurigene Discovery Technologies Limited Compounds and compositions for treating hematological disorders
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
MX2020006459A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
CN111655692B (zh) 2018-02-01 2023-10-10 日本烟草产业株式会社 含氮杂环酰胺化合物及其医药用途
JP2021513976A (ja) 2018-02-16 2021-06-03 ユーシービー バイオファルマ エスアールエル 医薬活性を有する６，５複素二環式環誘導体
JP2021514982A (ja) 2018-02-28 2021-06-17 ノバルティス アーゲー インドール−２−カルボニル化合物及びｂ型肝炎治療のためのそれらの使用
US20190284341A1 (en) 2018-03-14 2019-09-19 Sabic Global Technologies B.V. 3-oxo-2-alkylisoindoline diphthalonitrile monomers, methods of manufacture, thermosetting compositions comprising the same, and uses thereof
US20190284340A1 (en) 2018-03-14 2019-09-19 SABIC Global Technologies B.V 3-oxo-2-arylisoindoline diphthalonitrile monomers, methods of manufacture, thermosetting compositions comprising the same, and uses thereof
MX2020010390A (es) * 2018-04-02 2021-01-15 Chemocentryx Inc Profarmacos de antagonistas de c5ar biciclicos fusionados.
TWI707683B (zh) 2018-06-13 2020-10-21 美商輝瑞股份有限公司 Ｇｌｐ－１受體促效劑及其用途
WO2019239371A1 (en) * 2018-06-15 2019-12-19 Pfizer Inc. Glp-1 receptor agonists and uses thereof
CN112638909A (zh) 2018-06-27 2021-04-09 香港理工大学 具有抗菌活性的化合物
US11923622B2 (en) 2018-08-02 2024-03-05 Nokia Solutions And Networks Oy Antenna and wireless communication device
UY38434A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
AR116947A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
KR20210106447A (ko) 2018-11-22 2021-08-30 치루 레고르 테라퓨틱스 인코포레이티드 Glp-1r 효능제 및 그의 용도
CN111217842B (zh) 2018-11-26 2023-01-31 上海亚舸生物科技有限公司 一类螺环-二吡咯甲烷硼配合物/二吡咯甲川硼配合物及其制备方法和应用
CN111217796B (zh) 2018-11-26 2021-12-14 上海亚舸生物科技有限公司 一类螺环-二吡咯甲烷/二吡咯甲川化合物及其制备方法和应用
EP3889150A4 (en) 2018-12-25 2022-02-23 Shanghai Meiyue Biotech Development Co., Ltd. IRAQ INHIBITOR COMPOUND
WO2020163236A1 (en) 2019-02-04 2020-08-13 The General Hospital Corporation Treating long qt syndrome
KR20210152513A (ko) 2019-04-12 2021-12-15 치루 레고르 테라퓨틱스 인코포레이티드 Glp-1r 작용제 및 이의 용도
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
WO2021018023A1 (zh) 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 小分子glp-1受体调节剂
CN110804059B (zh) 2019-09-30 2024-03-12 郑州泰基鸿诺医药股份有限公司 氨基甲酸酯类化合物、药物组合物及其应用
BR112022007627A2 (pt) 2019-10-25 2022-07-12 Gilead Sciences Inc Compostos moduladores do glp-1r
BR112022009287A2 (pt) 2019-11-15 2022-08-09 Ildong Pharmaceutical Co Ltd Agonista do receptor de glp-1 e uso do mesmo
KR20220156535A (ko) 2020-02-07 2022-11-25 가셔브룸 바이오, 인크. 헤테로사이클릭 glp-1 작용제
US20230165846A1 (en) 2020-02-13 2023-06-01 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20230295154A1 (en) 2020-04-29 2023-09-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Also Published As

Publication number Publication date
US11926643B2 (en) 2024-03-12
IL295281A (en) 2022-10-01
US11492365B2 (en) 2022-11-08
MX2022009524A (es) 2023-01-11
PT4097099T (pt) 2024-07-19
EP4097099A4 (en) 2023-09-27
DK4097099T3 (da) 2024-07-15
WO2021155841A1 (en) 2021-08-12
CR20220371A (es) 2022-10-27
US20230174565A1 (en) 2023-06-08
AU2021216324A1 (en) 2022-08-25
KR20220156535A (ko) 2022-11-25
EP4097099B1 (en) 2024-06-26
CO2022011065A2 (es) 2022-10-31
CN115698003A (zh) 2023-02-03
CA3169975A1 (en) 2021-08-12
RS65877B1 (sr) 2024-09-30
PE20231066A1 (es) 2023-07-17
EP4097099A1 (en) 2022-12-07
FI4097099T3 (fi) 2024-07-30
CL2022002105A1 (es) 2023-03-17
JP2023513272A (ja) 2023-03-30
TW202142538A (zh) 2021-11-16
US20220213130A1 (en) 2022-07-07
CN115698003B (zh) 2024-10-11

Similar Documents

Publication Publication Date Title
DOP2022000158A (es) Agonistas heterocíclicos de glp-1
CO2023001263A2 (es) Agonistas del glp-1 heterocíclicos
DOP2022000117A (es) Inhibidores de kras g12c
GT200500379A (es) Derivados fusionados de pirazol y metodos de tratamiento de trastornos metabolicos con estos
AR038136A1 (es) Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
ECSP22049160A (es) Derivados de bencimidazol
ECSP23039172A (es) Compuestos de pirimidina, composiciones y aplicaciones médicas de esta
CO2022001814A2 (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
ECSP22083926A (es) Compuestos útiles para inhibir la quinasa ret
CO2023017151A2 (es) Inhibidores de ripk1 de nicotinamida
ECSP23070418A (es) Moduladores de sting (estimulador de genes de interferón)
BR112021020234A2 (pt) Terapia de combinação que compreende compostos da fórmula (i) e agonistas de receptor de glp-1
CL2023003168A1 (es) Moduladores de trex1
CO2023000117A2 (es) Derivados de sulfona
AR124720A1 (es) Derivados de pirazolamida
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
AR125059A1 (es) Degradadores selectivos del receptor de estrógeno
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
MX2020008230A (es) Derivados de ester butanoico sustituido con bisfenilo como inhibidores de nep.
ECSP23075535A (es) Compuestos cíclicos y métodos de uso
AR128426A1 (es) Compuestos heterocíclicos y métodos de uso
AR129367A1 (es) Derivados de pirazol como agonistas de sting
CO2024010726A2 (es) Compuestos heterocíclicos y métodos de uso
CO2022015823A2 (es) Derivados de n-(piperidin-4-il)benzamida de acción luminal